The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jonathan Chang - Leerink Partners LLC - Analyst
: Hi, guys. Thanks for taking my question. On the cabozantinib combination data, can you give us a sense of what the duration of response and/or
time on treatment metrics look like? Is there anything you can comment on there? Or is it still too early? Thank you.
Question: Peter Green - LifeSci Capital LLC - Analyst
: Hi. This is Peter Green on for Charles. Congrats on the data. Just a question on patients treated with cabo and darlifarnib. Any color on whether
those 4 of 12 responders that had, had prior best response of stable disease, whether they opt cabo due to progressive disease or for some other
reason, like toxicity. And then of those 12, did any of them have progressive disease or I guess, how many on cabo? Thanks.
Question: Reni Benjamin - Citizens JMP Securities LLC - Analyst
: Hey. Thanks, guys, for taking the questions and congratulations on the combination data. I guess my one question, maybe it's for Dr. Hanna, is how
do you view these combo results when compared to, let's say, the HIF-2 alpha plus cabo combinations? Any color would be great. Thanks.
Question: Philip Nadeau - Cowen and Company LLC - Analyst
: Good afternoon. Thanks for taking our question and congrats from us also on the data. Can you discuss in a bit more detail the design of the Phase
1b of 2806 and cabo? And in particular, what cabo patients will you be recruiting to the study? Will they be mostly cabo naive, cabo experienced
or a mix of the two? Thanks.
Question: Jason Zemansky - Bofa Merrill Lynch Asset Holdings Inc - Analyst
: Good afternoon. Congrats on the data and thanks so much for taking our question. I just wanted to home back to the waterfall plot for the 2806
cabo combination. I appreciate it's still somewhat early, but it looks like the majority of responses here are from the 5-milligram dose and appreciating
still dose escalating here. But curious, does that imply that there's a saturation point on what you can get from an FTI in this case? Or do you think
if you could increase the dose meaningfully, you could see more responses? Thanks.
Question: Peter Lawson - Barclays Services Corp - Analyst
: Great. Thank you so much for taking our question and congrats on all the data. On the dose response relationship for the combination with cabo,
that -- do you interpret that flat kind of exposure is this just still a reflection of limited sample size?
Question: Peter Lawson - Barclays Services Corp - Analyst
: And around 33%.
Question: David Dai - UBS AG - Analyst
: Great. Hey. Thanks for taking my questions and congrats on the data. So for the cabo combo, we did see pretty good safety with no overlapping
toxicity. But we did see slightly higher levels of diarrhea at 60 milligrams cabo dose. So maybe a question for Dr. Hanna. From a clinician's point of
view, what do you think about the rate of diarrhea in this combo? And how do you typically manage them?
Question: Jonathan Chang - Leerink Partners LLC - Analyst
: Hi, guys. Thanks for taking the follow-up. Maybe for Dr. Hanna, how would you compare your experience with darlifarnib versus tipifarnib? I know
it's not apples-to-apples here given the differences in the settings, but it would be great to hear your thoughts here.
| 
